新型体外肝脏代谢模型及其应用进展
Novel in vitro liver metabolism models and their applications progress
药物的肝脏代谢研究对药物开发、临床用药指导及药物安全性评估具有重要意义。传统体外肝脏模型虽应用广泛,但在功能维持、预测准确性与生理模拟方面存在局限性,促使多种新型体外肝脏模型被开发。现有综述多侧重于新型模型构建技术的介绍或性能的比较,而系统梳理不同新型模型在药物代谢研究中应用特点的文献较少。在综述近年来新型体外肝脏模型特点及其所采用新技术的基础上,本文进一步将模型功能特性与具体药物代谢研究应用场景对应分析,归纳其在代谢稳定性、代谢物鉴定与药物相互作用评估等方面的表现。以期为体外模型的合理选择与规范化应用提供参考,支持药物的临床前研究与临床应用。
Studies of hepatic drug metabolism are crucial for drug development, clinical dosing guidance, and assessment of drug safety. Although traditionalin vitro liver models have been widely used, their limitations in maintaining hepatic function, predictive accuracy, and physiological fidelity have spurred the development of various advanced in vitro liver models. Previous reviews have focused on the technologies used for constructing novel models or on comparative evaluations of their performance, whereas systematic analyses of the application characteristics of different advanced models in drug metabolism research remain limited. Based on a comprehensive review of recent advanced in vitro liver models and the novel technologies they employ, this article further aligns model functional characteristics with specific drug-metabolism research scenarios and summarizes their performance in metabolic stability assessment, metabolite identification, and the evaluation of drug–drug interactions. This review aims to provide guidance for the rational selection and standardized application of in vitro models, thereby supporting preclinical research and clinical use of drugs.
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
王颖, 潘国宇. 肝样细胞模型在药物肝脏代谢和毒性研究中的进展[J].药学进展, 2018, 42(8): 581-591. |
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
Guillouzo A, Corlu A, Aninat C, |
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
Nakakariya M, Ono M, Amano N, |
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
Foty R. A simple hanging drop cell culture protocol for generation of 3D spheroids[J].J Vis Exp, 2011(51): e2720. |
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
Huch M, Gehart H, Van Boxtel R, |
| [41] |
Hu H, Gehart H, Artegiani B, |
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
Ouchi R, Togo S, Kimura M, |
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
Fitzpatrick E, Wu Y, Dhadda P, |
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
Lopa S, Piraino F, Talò G, |
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
| [69] |
|
| [70] |
|
| [71] |
Milani N, Parrott N, Ortiz Franyuti D, |
| [72] |
|
| [73] |
Schimek K, Frentzel S, Luettich K, |
| [74] |
|
| [75] |
|
| [76] |
|
| [77] |
|
| [78] |
|
| [79] |
|
| [80] |
刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J].中国临床药理学与治疗学, 2021, 26(8): 889-913. |
| [81] |
|
| [82] |
Stringer R, Nicklin PL, Houston JB. Reliability of human cryopreserved hepatocytes and liver microsomes as in vitro systems to predict metabolic clearance[J].Xenobiotica, 2008, 38(10): 1313-1329. |
| [83] |
|
| [84] |
|
| [85] |
|
| [86] |
|
| [87] |
|
| [88] |
Bonn B, Svanberg P, Janefeldt A, |
| [89] |
|
| [90] |
|
| [91] |
|
| [92] |
|
| [93] |
|
| [94] |
U. S. Food and Drug Administration.Guidance for Industry; In vitro drug interaction studies - Cytochrome P450 enzyme and transporter mediated drug interactions[EB/OL].2020[2025-10-20].https://www.fda.gov/media/134582/download. |
| [95] |
|
| [96] |
|
| [97] |
|
| [98] |
|
| [99] |
|
| [100] |
|
| [101] |
|
| [102] |
|
| [103] |
|
| [104] |
|
| [105] |
|
| [106] |
|
| [107] |
|
| [108] |
|
| [109] |
|
| [110] |
孙广晨, 李宏宇, 陈江, |
中国医学科学院医学与健康科技创新工程项目(2021-I2M-5-011)
/
| 〈 |
|
〉 |